Trial Profile
Phase Ia single-dose trial of ShK 186 in healthy volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 May 2015
Price :
$35
*
At a glance
- Drugs Dalazatide (Primary)
- Indications Multiple sclerosis; Type 1 diabetes mellitus
- Focus Adverse reactions
- Sponsors Kineta
- 27 May 2013 Positive results were published in the Proceedings of the National Academy of Sciences, according to a Kineta media release.
- 01 Mar 2013 Status changed from recruiting to completed, according to a Kineta media release.
- 29 Jan 2013 New trial record